A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Completed

Plain-English translation of NCT05096221 on ClinicalTrials.gov ↗ · Source last updated July 2025 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

Trial locations(42 sites)

United States

Arkansas Children's, Little Rock, Arkansas

UC San Diego Altman Clinical and Translational Research Institute, La Jolla, California

UCLA Medical Center, Los Angeles, California

Lucile Packard Children's Hospital at Stanford, Palo Alto, California

University of California, Davis, Sacramento, California